Molecular Detection of Colorectal Neoplasia

Gastroenterology

Volumn 138, Issue 6, 2010, Pages 2127-2139

  Ahlquist, David A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Colorectal Cancer Screening; Molecular Tests; Stool DNA

Indexed keywords

APC PROTEIN; CYCLOOXYGENASE 2; K RAS PROTEIN;

ADENOMATOUS POLYP; ARTICLE; BLOOD ANALYSIS; CANCER PREVENTION; CANCER SCREENING; COLORECTAL ADENOMA; COLORECTAL CANCER; DNA EXTRACTION; DNA METHYLATION; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; NON INVASIVE PROCEDURE; OCCULT BLOOD; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 77951633198     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.01.055     Document Type: Article

References (107)

1. Center M.M., Jemal A., and Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 18 (2009) 1688-1694
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
3. Mariotto A.B., Yabroff K.R., Feuer E.J., et al. Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. Cancer Causes Control 17 (2006) 1215-1226
4. Osborn N.K., and Ahlquist D.A. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 128 (2005) 192-206
5. Lieberman D.A., Weiss D.G., Bond J.H., et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 343 (2000) 162-168
6. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351 (2004) 2704-2714
7. Ahlquist D.A., Sargent D.J., Loprinzi C.L., et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 149 (2008) 441-450 W81
8. Strul H., Kariv R., Leshno M., et al. The prevalence rate and anatomic location of colorectal adenoma and cancer detected by colonoscopy in average-risk individuals aged 40-80 years. Am J Gastroenterol 101 (2006) 255-262
9. Noffsinger A.E. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol 4 (2009) 343-364
10. Groff R.J., Nash R., and Ahnen D.J. Significance of serrated polyps of the colon. Curr Gastroenterol Rep 10 (2008) 490-498
11. Kakar S., Deng G., Cun L., et al. CpG island methylation is frequently present in tubulovillous and villous adenomas and correlates with size, site, and villous component. Hum Pathol 39 (2008) 30-36
12. Greenman C., Stephens P., Smith R., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007) 153-158
13. Wood L.D., Parsons D.W., Jones S., et al. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007) 1108-1113
14. Sjoblom T., Jones S., Wood L.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
15. Irizarry R.A., Ladd-Acosta C., Wen B., et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41 (2009) 178-186
16. Notterman D.A., Alon U., Sierk A.J., et al. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 61 (2001) 3124-3130
17. Sabates-Bellver J., Van der Flier L.G., de Palo M., et al. Transcriptome profile of human colorectal adenomas. Mol Cancer Res 5 (2007) 1263-1275
18. Friedman D.B., Hill S., Keller J.W., et al. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 4 (2004) 793-811
19. Shen L., Toyota M., Kondo Y., et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 104 (2007) 18654-18659
20. Zou H., Harrington J.J., Shire A.M., et al. Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev 16 (2007) 2686-2696
21. Ostwald C., Linnebacher M., Weirich V., et al. Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int J Oncol 35 (2009) 321-327
22. Ahlquist D.A., Harrington J.J., Burgart L.J., et al. Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol 31 (2000) 51-57
23. Liotta L.A., Rao C.N., and Wewer U.M. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 55 (1986) 1037-1057
24. Stetler-Stevenson W.G., Aznavoorian S., and Liotta L.A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9 (1993) 541-573
25. Krasna M.J., Flancbaum L., Cody R.P., et al. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 61 (1988) 1018-1023
26. Sastre J., Maestro M.L., Puente J., et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 19 (2008) 935-938
27. Feng B., Yue F., and Zheng M.H. Urinary markers in colorectal cancer. Adv Clin Chem 47 (2009) 45-57
28. Frisch S.M., and Screaton R.A. Anoikis mechanisms. Curr Opin Cell Biol 13 (2001) 555-562
29. Shanmugathasan M., and Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int 50 (2000) 273-279
30. Loktionov A., O'Neill I.K., Silvester K.R., et al. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin Cancer Res 4 (1998) 337-342
31. Davies R.J., Freeman A., Morris L.S., et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 359 (2002) 1917-1919
32. Albaugh G.P., Iyengar V., Lohani A., et al. Isolation of exfoliated colonic epithelial cells, a novel, non-invasive approach to the study of cellular markers. Int J Cancer 52 (1992) 347-350
33. Loktionov A. Cell exfoliation in the human colon: myth, reality and implications for colorectal cancer screening. Int J Cancer 120 (2007) 2281-2289
34. Eckburg P.B., Bik E.M., Bernstein C.N., et al. Diversity of the human intestinal microbial flora. Science 308 (2005) 1635-1638
35. Limburg P.J., Ahlquist D.A., Gilbert J.A., et al. Immunodiscrimination of colorectal neoplasia using MUC1 antibodies: discrepant findings in tissue versus stool. Dig Dis Sci 45 (2000) 494-499
36. White V., Scarpini C., Barbosa-Morais N.L., et al. Isolation of stool-derived mucus provides a high yield of colonocytes suitable for early detection of colorectal carcinoma. Cancer Epidemiol Biomarkers Prev 18 (2009) 2006-2013
37. Tamkovich S.N., Cherepanova A.V., Kolesnikova E.V., et al. Circulating DNA and DNase activity in human blood. Ann N Y Acad Sci 1075 (2006) 191-196
38. Aoyagi T., Wada T., Kojima F., et al. Three main components in plasma proteases and their relation to the renin-angiotensin system. Biotechnol Appl Biochem 12 (1990) 258-263
39. Su Y.H., Wang M., Aiamkitsumrit B., et al. Detection of a K-ras mutation in urine of patients with colorectal cancer. Cancer Biomark 1 (2005) 177-182
40. Smith A.J., Stern H.S., Penner M., et al. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 54 (1994) 5527-5530
41. Yamashita N., Minamoto T., Ochiai A., et al. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 108 (1995) 434-440
42. Chan A.O., Broaddus R.R., Houlihan P.S., et al. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 160 (2002) 1823-1830
43. Gosselin K., Martien S., Pourtier A., et al. Senescence-associated oxidative DNA damage promotes the generation of neoplastic cells. Cancer Res 69 (2009) 7917-7925
44. Klaassen C.H., Jeunink M.A., Prinsen C.F., et al. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin Chem 49 (2003) 1185-1187
45. Diehl F., Schmidt K., Durkee K.H., et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 135 (2008) 489-498
46. Zou H., Taylor W.R., Harrington J.J., et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 136 (2009) 459-470
47. Ahlquist D.A., Skoletsky J.E., Boynton K.A., et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119 (2000) 1219-1227
48. Diehl F., Li M., Dressman D., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102 (2005) 16368-16373
49. Dong S.M., Traverso G., Johnson C., et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 93 (2001) 858-865
50. Olson J., Whitney D.H., Durkee K., et al. DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn Mol Pathol 14 (2005) 183-191
51. Zou H., Harrington J.J., Klatt K.K., et al. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 15 (2006) 1115-1119
52. Oberwalder M., Zitt M., Wontner C., et al. SFRP2 methylation in fecal DNA-a marker for colorectal polyps. Int J Colorectal Dis 23 (2008) 15-19
53. Grutzmann R., Molnar B., Pilarsky C., et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 3 (2008) e3759
54. Chen W.D., Han Z.J., Skoletsky J., et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97 (2005) 1124-1132
55. Tsujii M., Kawano S., and DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 94 (1997) 3336-3340
56. Ahmed F.E., Vos P., James S., et al. Transcriptomic molecular markers for screening human colon cancer in stool and tissue. Cancer Genomics Proteomics 4 (2007) 1-20
57. Bustin S.A., Gyselman V.G., Williams N.S., et al. Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients. Br J Cancer 79 (1999) 1813-1820
58. Bresalier R.S., Byrd J.C., Tessler D., et al. A circulating ligand for galectin-3 is a haptoglobin-related glycoprotein elevated in individuals with colon cancer. Gastroenterology 127 (2004) 741-748
59. Mandel J.S., Bond J.H., Church T.R., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328 (1993) 1365-1371
60. Hardcastle J.D., Chamberlain J.O., Robinson M.H., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348 (1996) 1472-1477
61. Kronborg O., Fenger C., Olsen J., et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348 (1996) 1467-1471
62. Heresbach D., Manfredi S., D'Halluin P.N., et al. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol 18 (2006) 427-433
63. Ahlquist D.A., McGill D.B., Fleming J.L., et al. Patterns of occult bleeding in asymptomatic colorectal cancer. Cancer 63 (1989) 1826-1830
64. Ahlquist Y.G., and Young G.P. Approach to the patient with occult gastrointestinal bleeding. In: Yamada T. (Ed). Principles of clinical gastroenterology (2008), Wiley-Blackwell, Chichester; Hoboken 152-169
65. Allison J.E., Sakoda L.C., Levin T.R., et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 99 (2007) 1462-1470
66. Levin B., Lieberman D.A., McFarland B., et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58 (2008) 130-160
67. Morikawa T., Kato J., Yamaji Y., et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129 (2005) 422-428
68. Sidransky D., Tokino T., Hamilton S.R., et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256 (1992) 102-105
69. Gupta A.K., Melton III L.J., Petersen G.M., et al. Changing trends in the incidence, stage, survival, and screen-detection of colorectal cancer: a population-based study. Clin Gastroenterol Hepatol 3 (2005) 150-158
70. Park S.Y., Kim B.C., Shin S.J., et al. Proximal shift in the distribution of adenomatous polyps in Korea over the past ten years. Hepatogastroenterology 56 (2009) 677-681
71. Rex D.K., Johnson D.A., Anderson J.C., et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 104 (2009) 739-750
72. Whitlock E.P., Lin J.S., Liles E., et al. Screening for colorectal cancer: a targeted, updated systematic review for the US Preventive Services Task Force. Ann Intern Med 149 (2008) 638-658
73. Huang Z., Li L., and Wang J. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 52 (2007) 2287-2291
74. Itzkowitz S.H., Jandorf L., Brand R., et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 5 (2007) 111-117
75. Wang D.R., and Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol 14 (2008) 524-531
76. Nagasaka T., Tanaka N., Cullings H.M., et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst 101 (2009) 1244-1258
77. Glockner S.C., Dhir M., Yi J.M., et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 69 (2009) 4691-4699
78. Ausch C., Kim Y.H., Tsuchiya K.D., et al. Comparative analysis of PCR-based biomarker assay methods for colorectal polyp detection from fecal DNA. Clin Chem 55 (2009) 1559-1563
79. Li M., Chen W.D., Papadopoulos N., et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 27 (2009) 858-863
80. Leung W.K., To K.F., Man E.P., et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol 102 (2007) 1070-1076
81. Jiang X., Harrington J.J., Mahoney D.W., et al. Detection of colorectal neoplasia by stool DNA testing: high discrimination with multi-marker quantitation. Gastroenterology 134 Suppl 1 (2008) A-484
82. Zou H., Jian X., Harrington J.J., et al. Quantitative stool DNA testing for detection of both colorectal cancer and advanced adenoma. Gastroenterology (on-line) 136 Suppl 1 (2009) A-625
83. Baek Y.H., Chang E., Kim Y.J., et al. Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis Colon Rectum 52 (2009) 1452-1459 discussion 1459-1463
84. Hussain FTN, Harrington JJ, Yab TC, et al. Detection of serrated colorectal polyps by stool DNA testing. Presented at the 2010 Gastrointestinal Cancers Symposium, Orlando FL, January 2010.
85. Ahlquist D.A. Next-generation stool DNA testing: expanding the scope. Gastroenterology 136 (2009) 2068-2073
86. Zou H., Harrington J.J., Taylor W.R., et al. Pan-detection of gastrointestinal neoplasms by stool DNA testing: establishment of feasibility. Gastroenterology 136 Suppl 1 (2009) A625
87. Takai T., Kanaoka S., Yoshida K., et al. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 18 (2009) 1888-1893
88. Bezabeh T., Somorjai R., Dolenko B., et al. Detecting colorectal cancer by 1H magnetic resonance spectroscopy of fecal extracts. NMR Biomed 22 (2009) 593-600
89. Tsouma A., Aggeli C., Pissimissis N., et al. Circulating tumor cells in colorectal cancer: detection methods and clinical significance. Anticancer Res 28 (2008) 3945-3960
90. Lofton-Day C., Model F., Devos T., et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 54 (2008) 414-423
91. deVos T., Tetzner R., Model F., et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55 (2009) 1337-1346
92. Lee B.B., Lee E.J., Jung E.H., et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 15 (2009) 6185-6191
93. Liu X.P., Shen J., Li Z.F., et al. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest 24 (2006) 747-753
94. Hurst N.G., Stocken D.D., Wilson S., et al. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 97 (2007) 971-977
95. Leman E.S., Schoen R.E., Weissfeld J.L., et al. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res 67 (2007) 5600-5605
96. Walgenbach-Brunagel G., Burger B., Leman E.S., et al. The use of a colon cancer associated nuclear antigen CCSA-2 for the blood based detection of colon cancer. J Cell Biochem 104 (2008) 286-294
97. Kim H.J., Kang H.J., Lee H., et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res 8 (2009) 1368-1379
98. Habermann J.K., Roblick U.J., Luke B.T., et al. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 131 (2006) 1020-1029 quiz 1284
99. Japink D., Leers M.P., Sosef M.N., et al. CEA in activated macrophages. New diagnostic possibilities for tumor markers in early colorectal cancer. Anticancer Res 29 (2009) 3245-3251
100. Kraus S., Galazan L., Naumov I., et al. S1128 identification of CD24, a novel biomarker for the early detection of colorectal cancer (CRC), using peripheral blood mononuclear cells. Gastroenterology 134 Suppl 1 (2009) A184
101. Hsu W.Y., Chen W.T., Lin W.D., et al. Analysis of urinary nucleosides as potential tumor markers in human colorectal cancer by high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Clin Chim Acta 402 (2009) 31-37
102. Lasser K.E., Ayanian J.Z., Fletcher R.H., et al. Barriers to colorectal cancer screening in community health centers: a qualitative study. BMC Fam Pract 9 (2008) 15
103. Vernon S.W. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 89 (1997) 1406-1422
104. Croswell J.M., Kramer B.S., Kreimer A.R., et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med 7 (2009) 212-222
105. Song K., Fendrick A.M., and Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 126 (2004) 1270-1279
106. Parekh M., Fendrick A.M., and Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 27 (2008) 697-712
107. Subramanian S., Bobashev G., and Morris R.J. Modeling the cost-effectiveness of colorectal cancer screening: policy guidance based on patient preferences and compliance. Cancer Epidemiol Biomarkers Prev 18 (2009) 1971-1978